David Amsellem
Stock Analyst at Piper Sandler
(4.24)
# 522
Out of 4,641 analysts
129
Total ratings
55.56%
Success rate
13.26%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COLL Collegium Pharmaceutical | Reiterates: Neutral | $37 | $36.19 | +2.24% | 6 | Oct 11, 2024 | |
| INDV Indivior | Reiterates: Overweight | $22 → $15 | $8.71 | +72.22% | 3 | Oct 11, 2024 | |
| ANIP ANI Pharmaceuticals | Initiates: Overweight | $68 | $60.08 | +13.18% | 1 | Oct 11, 2024 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $38 → $67 | $48.92 | +36.96% | 5 | Sep 18, 2024 | |
| SUPN Supernus Pharmaceuticals | Downgrades: Neutral | $41 → $36 | $33.71 | +6.79% | 15 | Sep 11, 2024 | |
| NBIX Neurocrine Biosciences | Upgrades: Overweight | $131 → $159 | $116.78 | +36.15% | 8 | Aug 29, 2024 | |
| RVNC Revance Therapeutics | Maintains: Overweight | $11 → $6 | $5.29 | +13.42% | 9 | Aug 9, 2024 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Overweight | $71 → $66 | $50.38 | +31.00% | 6 | Aug 8, 2024 | |
| BHC Bausch Health Companies | Downgrades: Underweight | $9 → $3 | $8.11 | -63.01% | 7 | Aug 2, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $188 → $166 | $113.10 | +46.77% | 10 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $17.63 | +138.23% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $19 → $20 | $18.38 | +8.81% | 9 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 → $3 | $3.02 | -0.66% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $24 | $17.35 | +38.33% | 5 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $5.10 | +96.08% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $39 | $28.10 | +38.79% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 → $13 | $11.67 | +11.40% | 5 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $8.50 | -5.88% | 3 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $23 | $13.68 | +68.13% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $4.08 | +414.71% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $92.40 | +22.30% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $1 | $0.27 | +271.75% | 3 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $34.86 | +20.48% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $3 | $0.79 | +279.55% | 1 | Aug 11, 2023 |
Collegium Pharmaceutical
Oct 11, 2024
Reiterates: Neutral
Price Target: $37
Current: $36.19
Upside: +2.24%
Indivior
Oct 11, 2024
Reiterates: Overweight
Price Target: $22 → $15
Current: $8.71
Upside: +72.22%
ANI Pharmaceuticals
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $60.08
Upside: +13.18%
Corcept Therapeutics
Sep 18, 2024
Maintains: Overweight
Price Target: $38 → $67
Current: $48.92
Upside: +36.96%
Supernus Pharmaceuticals
Sep 11, 2024
Downgrades: Neutral
Price Target: $41 → $36
Current: $33.71
Upside: +6.79%
Neurocrine Biosciences
Aug 29, 2024
Upgrades: Overweight
Price Target: $131 → $159
Current: $116.78
Upside: +36.15%
Revance Therapeutics
Aug 9, 2024
Maintains: Overweight
Price Target: $11 → $6
Current: $5.29
Upside: +13.42%
Amphastar Pharmaceuticals
Aug 8, 2024
Maintains: Overweight
Price Target: $71 → $66
Current: $50.38
Upside: +31.00%
Bausch Health Companies
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $8.11
Upside: -63.01%
Jazz Pharmaceuticals
Aug 1, 2024
Maintains: Overweight
Price Target: $188 → $166
Current: $113.10
Upside: +46.77%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $17.63
Upside: +138.23%
May 13, 2024
Reiterates: Overweight
Price Target: $19 → $20
Current: $18.38
Upside: +8.81%
May 10, 2024
Reiterates: Overweight
Price Target: $4 → $3
Current: $3.02
Upside: -0.66%
Apr 29, 2024
Maintains: Overweight
Price Target: $22 → $24
Current: $17.35
Upside: +38.33%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $5.10
Upside: +96.08%
Apr 1, 2024
Reiterates: Overweight
Price Target: $39
Current: $28.10
Upside: +38.79%
Mar 28, 2024
Reiterates: Neutral
Price Target: $11 → $13
Current: $11.67
Upside: +11.40%
Mar 21, 2024
Maintains: Overweight
Price Target: $6 → $8
Current: $8.50
Upside: -5.88%
Mar 5, 2024
Maintains: Overweight
Price Target: $18 → $23
Current: $13.68
Upside: +68.13%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $4.08
Upside: +414.71%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $92.40
Upside: +22.30%
Nov 14, 2023
Downgrades: Neutral
Price Target: $12 → $1
Current: $0.27
Upside: +271.75%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $34.86
Upside: +20.48%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $3
Current: $0.79
Upside: +279.55%